Patents by Inventor Michael T. Stumpp
Michael T. Stumpp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11332501Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: November 2, 2018Date of Patent: May 17, 2022Assignee: MOLECULAR PARTNERS AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Publication number: 20190263869Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: November 2, 2018Publication date: August 29, 2019Inventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Patent number: 10155791Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: August 26, 2016Date of Patent: December 18, 2018Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Publication number: 20160362453Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: August 26, 2016Publication date: December 15, 2016Inventors: Talitha BAKKER, Michael T. STUMPP, Hans Kaspar BINZ, Douglas PHILLIPS, Ignacio DOLADO, Patrik FORRER, Frieder W. MERZ, Ivo SONDEREGGER, Daniel STEINER, Maya GULOTTI-GEORGIEVA, Johan ABRAM SALIBA
-
Publication number: 20160289285Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: April 1, 2016Publication date: October 6, 2016Inventors: Talitha BAKKER, Michael T. STUMPP, Hans Kaspar BINZ, Douglas PHILLIPS, Ignacio DOLADO, Patrik FORRER, Frieder W. MERZ, Ivo SONDEREGGER, Daniel STEINER, Maya GULOTTI-GEORGIEVA, Johan ABRAM SALIBA
-
Patent number: 9458211Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: April 1, 2016Date of Patent: October 4, 2016Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Patent number: 9447142Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: GrantFiled: August 26, 2014Date of Patent: September 20, 2016Assignee: University of ZurichInventors: Daniel Steiner, Patrik Forrer, Michael T. Stumpp, Andreas Pluckthun
-
Publication number: 20150057186Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Daniel STEINER, Patrik FORRER, Michael T. STUMPP, Andreas Plückthun
-
Patent number: 8846577Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: GrantFiled: June 30, 2006Date of Patent: September 30, 2014Assignee: University of ZurichInventors: Daniel Steiner, Patrik Forrer, Michael T. Stumpp, Andreas Plückthun
-
Publication number: 20110118146Abstract: The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.Type: ApplicationFiled: June 30, 2006Publication date: May 19, 2011Inventors: Daniel Steiner, Patrik Forrer, Michael T. Stumpp, Andreas Plückthun